



November 28, 2017

MicroBase Technology Corporation
% Paul Dryden
Consultant
MicroBase Technology Corporation c/o ProMedic, LLC.
24301 Woodsage Dr.
Bonita Springs, Florida 34134

Re: K170916
Trade/Device Name: Portable Nebulizer
Regulation Number: 21 CFR 868.5630
Regulation Name: Nebulizer
Regulatory Class: Class II
Product Code: CAF
Dated: October 19, 2017
Received: October 23, 2017

Dear Paul Dryden:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/>) and CDRH Learn (<http://www.fda.gov/Training/CDRHLearn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<http://www.fda.gov/DICE>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Tara A. Ryan -S

for

Tina Kiang, Ph.D.

Acting Director

Division of Anesthesiology,

General Hospital, Respiratory,

Infection Control, and Dental Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K170916

Device Name

Portable Nebulizer

Indications for Use (Describe)

The Portable Nebulizer is a vibrating mesh nebulizer system designed to aerosolize liquid medications for inhalation by the patient. The device may be used with pediatric (5 years and older), defined by the prescribed medication, and adult patients in hospital/institutional settings, home care use, schools, and long term care facilities.

Type of Use (Select one or both, as applicable)

☒ Prescription Use (Part 21 CFR 801 Subpart D)

☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

MicroBase Technology Corporation
No. 756, Jiadong Road
Bade District, Taoyuan City 33464, Taiwan

Official Contact: Molly Hsieh
General Manager
Tel - 011-886- 3-376-7555
Fax - 011-886- 3-376-7557

Proprietary or Trade Name: Portable Nebulizer

Common/Usual Name: Nebulizer (Direct Patient Interface)

Classification Name: Nebulizer (Direct Patient Interface)
Product Classification – CAF
21 CFR 868.5630
Class II

Predicate Devices: K062263 – Omron NE-U22

Device Description:

The Portable Nebulizer is a small, handheld, internally powered general purpose nebulizer which utilizes vibrating mesh technology to generate aerosol.

Components

The **Medication Cup** contains the nebulizing module where aerosol will be generated. Prescribed medication is placed in the Cup, nebulized and inhaled via the integral mouthpiece.

The Medication Cup is single patient, multi-use. Cleaning is performed after each use by rinsing with distilled water and disinfected via immersion in boiled water for 10 minutes. The performance met its specification criteria of 90 days.

The cup medication capacity is 6 ml.

The **Main Unit** contains the 2 “AA” batteries and firmware to control the vibrating mesh module in the Medication Cup.

Portable Nebulizer aerosolizes upon turning on by pressing the ON/OFF button and turns off by pressing again or automatically after treatment completion in 30 minutes. To monitor nebulization status and device operating condition, there are different LED colors shown. Normal working condition is indicated by a green while an orange color signifies a malfunction.

There is one model of the subject device.

Indications for Use:

The Portable Nebulizer is a vibrating mesh nebulizer system designed to aerosolize liquid medications for inhalation by the patient. The device may be used with pediatric (5 years and older), defined by the prescribed medication, and adult patients in hospital/institutional settings, home care use, schools, and long term care facilities.

Principle of Operation / Technology

The Portable Nebulizer operates by electrically activating piezoelectric ceramic actuator (PZT) which then transduces the vibration generated to the adjacent supporting plate and polymer mesh bearing numerous apertures. The vibration actively pushes out the liquid medication by physically breaking surface tension of the solution through mesh holes thereby achieving final nebulization. Aerosol generation can subsequently be modulated the vibration frequency that is controlled by the firmware stored within Main Unit to maintain a frequency of approximate 117 kHz, nebulization rate of ≥ 0.25 ml/min and a power consumption of <1.5 W.

Table 1 – Performance Specifications

Features	Proposed Portable Nebulizer
Indications for use	The Portable Nebulizer is a vibrating mesh nebulizer system designed to aerosolize liquid medications for inhalation by the patient. The device may be used with pediatric (5 years old or greater), defined by the prescribed medication, and adult patients in hospital/institutional settings, home care use, schools, and long term care facilities.
Environment of Use	
Patient Population	
Contraindications	None
Vibrating mesh technology	Yes
Software driven	Yes - firmware
Patient Interface	Mouthpiece
Nebulizer components cleanable	Yes – Medication Cup and mouthpiece
Operating conditions	10°C to 40°C 30% to 85% RH
Storage conditions	-20°C to 70°C, 20% to 75% RH
Power Source	DC – 2 – AA Alkaline batteries

Comparison to Predicate

Tables 2 provides a comparison of the proposed device to the predicate.

Table 2 – Comparison of Proposed vs. Predicate Device

Features	Predicate Omron NE-U22 K062263	Proposed Portable Nebulizer
Indications for use	The Omron NE-U22 is an ultrasonic (vibrating mesh) nebulizer system designed to aerosolize liquid medications for inhalation by the patient.	The Portable Nebulizer is a vibrating mesh nebulizer system designed to aerosolize liquid medications for inhalation by the patient.
Patient Population	The device may be used with pediatric and adult patients	The device may be used with pediatric (5 years and older), defined by the prescribed medication, and adult patients
Environment of Use	in the home, hospital, and sub-acute care settings. .	in hospital/institutional settings, home care use, schools, and long term care facilities.
Contraindications	It is not intended for use with Pentamidine.	None
Principle of Operation	Vibrating mesh	Vibrating mesh
Aerosolization	Continuous during inhalation and exhalation	Continuous during inhalation and exhalation
Compressed gas source	None needed	None needed
Reservoir volume	7 ml	6 ml
Nebulization rate	0.25 ml/min to 0.9 ml/min	≥ 0.25 ml/min
Duration of Use	Single patient, multi-use	Single patient, multi-use
Nebulizer components cleanable	Yes	Yes
Software driven	No	Yes
Power source	2 – “AA” Battery	2 – “AA” battery
Power consumption	1.5 W	< 1.5 W
Weight	97 gm w/o batteries	74 gm w/o batteries
Dimensions (mm)	51 x 38 x 104	77 x 41 x 73
Operating Conditions	0 to 45°C / 30-85% RH	10 to 40°C / 30-85% RH
Storage Conditions	-25 to + 70°C / 10-90% RH	-20 to + 70°C / 20-75% RH
User interface	On/Off switch LED indicators	On/Off switch LED indicators
Standards met	ES60601-1 IEC 60601-1-2	ES60601-1 IEC 60601-1-2 IEC 60601-1-6 IEC 60601-1-11
Performance		
Materials per ISO 10993-1	External Communicating (Indirect gas pathway) Tissue / Bone / Dentin communicating Duration of Use – permanent (> 30 days) And Surface Contact Mucosal membrane Duration of Use – permanent (> 30 days)	External Communicating (Indirect gas pathway) Tissue / Bone / Dentin communicating Duration of Use – permanent (> 30 days) And Surface Contact Mucosal membrane Duration of Use – permanent (> 30 days)
MMAD	MMAD, GSD, Total Respirable Dose, and Total Dose were substantially equivalent to the predicate.	
GSD		
Total Respirable Dose		
Total Dose		

Features	Predicate Omron NE-U22 K062263	Proposed Portable Nebulizer
Software		
Level of Concern	Moderate	Moderate
Device Specific	Yes	Yes
Dependent on external devices	No	No
Signals	LED and tone sounds	LED and tone sounds

Substantial Equivalence Discussion

The Portable Nebulizer is viewed as substantially equivalent to the predicate device because:

Indications for Use – The proposed indications for use are to aerosolize commonly prescribed medications.

Discussion - The indications for use are identical for the proposed device and the predicate – K062263 – Omron NE-U22 nebulizer.

The exclusion of the reference to pentamidine is no longer included in nebulizer indications for use, K150591, and has been removed.

Patient Population – The patient population of adult and pediatric (defined by the prescribed medication) patients that is consistent with the indications for the aerosol medication. This is similar to the predicate – K062263 – Omron NE-U22 nebulizer.

Discussion - The patient population is similar for the proposed device and the predicate – K062263 – Omron NE-U22 nebulizer. The predicate does not describe the pediatric population, however other reference nebulizers have defined the patient population as “pediatric (2 years and older) and / or as “defined by the prescribed medication” – K150591 – Besmed. Thus the differences in the description of the patient population compared to the predicate can be found to be substantially equivalent.

Environment of Use – The proposed environments of use are common and usual for handheld nebulizers, namely Hospital/institutional settings, home care use, schools and long term care facilities.

Discussion – The environment of use is identical for the proposed device and the predicate – K062263 – Omron NE-U22 nebulizer.

Technology – The design as a vibrating mesh nebulizer which is the identical principle of operation.

Discussion – The technology is identical for the proposed device as compared to the predicate – K062263 – Omron NE-U22 nebulizer.

Summary of Non-Clinical Performance Testing

We performed a number of non-clinical tests to demonstrate that the Portable Nebulizer is equivalent to the predicate K062263 – Omron NE-U22 nebulizer.

- Shelf-life, Useful-life, and Durability Testing
- Simulated Life Cycle testing
- Cleaning
- Electrical Safety, EMC, EMC

- Particle Characterization per Cascade Impactor
- Intra- and Inter- Sample Variability

Electrical Safety and Electromagnetic Compatibility (EMC)

Electrical safety and EMC testing were conducted on the device. Testing established that, with respect to electrical safety, the device meets the applicable requirements of: (1) IEC 60601-1:2012; (2) IEC 60601-1-2:2007; (3) IEC 60601-1-11:2012.

Software Verification and Validation Testing

Verification and validation testing was conducted in accordance with, and documentation was provided as recommended by FDA's Guidance 337, "*Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices*". The software for this device is of a "moderate" level of concern, since a failure or latent flaw in the software could lead to a delay in delivery of appropriate medical care.

Biocompatibility

The materials in patient / drug contact are characterized as:

- External Communicating (Indirect gas pathway)
- Tissue / Bone / Dentin communicating
- Duration of Use – permanent (> 30 days)

And

- Surface Contact
- Mucosal membrane
- Duration of Use – permanent (> 30 days)

Discussion - We performed ISO 10993-1 tests to support biocompatibility. They included:

- Cytotoxicity
- Sensitization
- Irritation
- Sub-chronic Systemic toxicity
- Acute Systemic Toxicity
- Leachable and Extractables with Risk Based Assessment
- Gas Emission VOC plus Inorganic compounds - CO, CO₂, and Ozone
- PM_{2.5}

Under the parameters of the tests it is concluded that they are biocompatible, and that there are no new issues of biocompatibility regarding their use as intended.

Cleaning and Disinfection Validation

Microbiological efficiency control tests were conducted in order to validate the nebulizer cleaning and disinfection methods in the IFU. Testing involved validation of: (1) a manual cleaning method and a thermal disinfection method. All testing concluded that the nebulizer could be cleaned and disinfected effectively by use of the methods stated in the IFU.

Particle Characterization

Comparative aerosol characterization (particle size distribution) performed between the subject and predicate device. The following tables summarize the results, in all the results very similar compared to that of the predicate.

Table 3 – Comparative Aerosol Performance – Adult Flow Rate – 28 lpm

Features	Predicate Omron NE-U22 K062263	Proposed Portable Nebulizer
Particle Characterization per Cascade Impactor @ 28 lpm – Adult Flow		
Total Dose (ug)	Albuterol – 1232 - 1362 Ipratropium – 240 - 295 Cromolyn – 7648 - 9249	Albuterol – 1719 – 2082* Ipratropium – 347 – 403* Cromolyn – 13372 – 14329*
Particle size (MMAD) (Microns)	Albuterol – 2.5 – 3.6 Ipratropium – 1.8 – 4.2 Cromolyn – 1.9 – 3.0	Albuterol – 1.9 – 2.8* Ipratropium – 2.0 – 2.7 Cromolyn – 2.1 – 2.8
Geometric Std. Dev. (GSD)	Albuterol – 2.1 – 3.0 Ipratropium – 2.4 – 3.7 Cromolyn – 2.3 – 3.0	Albuterol – 1.9 – 2.6 Ipratropium – 2.1 – 2.6* Cromolyn – 2.3 – 2.8
Total Respirable Dose (0.5-5 microns)	Albuterol – 659 – 965 Ipratropium – 97 - 201 Cromolyn – 4337 - 6601	Albuterol – 1274 – 1487* Ipratropium – 237 – 275* Cromolyn – 8645 – 9954*
Coarse Particle Dose (>4.7 micron)	Albuterol – 373 - 631 Ipratropium – 82 - 145 Cromolyn – 2312 - 3206	Albuterol – 279 - 726 Ipratropium – 85 - 138 Cromolyn – 3723 – 4676*
Fine Particle Dose (<4.7 micron)	Albuterol – 657 - 934 Ipratropium – 95 - 213 Cromolyn – 4607 - 6771	Albuterol – 1290 – 1506* Ipratropium – 241 – 286* Cromolyn – 8995 – 10307*
Ultra-fine Particle Dose (< 1.0 micron)	Albuterol – 97 - 154 Ipratropium – 21 - 67 Cromolyn – 1211 - 1574	Albuterol – 215 – 354* Ipratropium – 49 – 68 Cromolyn – 1524 – 2736*
Confidence level of testing	95% confidence level	95% confidence level

Overall the results support substantial equivalence argument.

Table 4 – Comparative Aerosol Performance – Pediatric Flow Rate – 12 lpm

Features	Predicate Omron NE-U22 K062263	Proposed Portable Nebulizer
Particle Characterization per Cascade Impactor @ 12 lpm – Pediatric Flow		
Total Dose (ug)	Albuterol – 1967-2379 Ipratropium – 411-451 Cromolyn – 16066-17807	Albuterol – 2159-2592 Ipratropium – 429-505 Cromolyn – 17733-18426
Particle size (MMAD) (Microns)	Albuterol – 5.09 – 6.91 Ipratropium – 6.50 – 6.97 Cromolyn – 6.60 – 6.86	Albuterol – 3.31 – 4.95* Ipratropium – 4.34 – 5.72* Cromolyn – 3.68 – 5.38*
Geometric Std. Dev. (GSD)	Albuterol – 2.25 – 2.85 Ipratropium – 2.76 – 3.09 Cromolyn – 2.71 – 3.52	Albuterol – 2.03 – 2.72 Ipratropium – 2.39 – 3.50 Cromolyn – 2.56 – 2.89
Total Respirable Dose (0.5-5 microns)	Albuterol – 711-942 Ipratropium – 140-160 Cromolyn – 5559-6501	Albuterol – 1071-1596* Ipratropium – 198-219* Cromolyn – 7925-10601*
Coarse Particle Dose (>4.7 micron)	Albuterol – 1121-1626 Ipratropium – 273-302 Cromolyn – 10302-11415	Albuterol – 913-1214 Ipratropium – 213-291 Cromolyn – 7240-10277

Features	Predicate Omron NE-U22 K062263	Proposed Portable Nebulizer
Fine Particle Dose (<4.7 micron)	Albuterol – 743-856 Ipratropium – 134-153 Cromolyn – 5737-6418	Albuterol – 1026-1597* Ipratropium – 212-218* Cromolyn – 8135-10507*
Ultra-fine Particle Dose (< 1.0 micron)	Albuterol – 65-80 Ipratropium – 14-17 Cromolyn – 808-969	Albuterol – 31-220 Ipratropium – 14-44 Cromolyn – 887-1904
Confidence level of testing	95% confidence level	95% confidence level

Overall the results support substantial equivalence argument.

Particle size characterization (MMAD) was verified after two years of real-time aging using both cascade impactor technique and laser light scattering technique.

Substantial Equivalence Conclusion

As detailed, the indications for use, patient population, environment of use, technology or principle of operation and performance are substantially equivalent.

The differences between the proposed Portable Nebulizer and the predicate – K062263 – Omron Model NE-U22 based upon the comparative performance testing we can conclude that the proposed device can be determined to be substantially equivalent to the predicate.